FMP
Savara Inc.
SVRA
NASDAQ
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
3.2 USD
-0.05 (-1.56%)
We are unable to load the chart at this time.
Mr. Matthew Pauls J.D., M.B.A.
Healthcare
Biotechnology
NASDAQ
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
0001160308
US8051111016
805111101
Building III
512 614 1848
US
37
Apr 28, 2017
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001160308
NASDAQ
Biotechnology
Healthcare
805111101
US8051111016
US
3.2
1.02
1.44M
549.18M
-
2.815-5.7
0
-
-
-
-
-7.44
-
https://www.savarapharma.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.